PROGRAMME
Wednesday 19 March
12:30-13:30
Registration
13.30-14.30
Opening keynote
Chair: François Moreau Gaudry, Oumeya Adjali
​
13:30 Welcome
​
13:45 Gregory Newby, John Hopkins University
INV01 Precision genome editing to treat genetic disease
​
14.30-16.30
Session 1: Advances and challenges for gene editing technology
Chairs:
​
​14:30 Anna Cereseto, University of Trento
INV02: Expanding the genome editing toolbox through the identification and evolution of novel RNA guided nucleases.
15:00 Aurélie Bedel, University of Bordeaux, INSERM U1312
INV03: Challenges for CRISPR-Cas9 genotoxicity: detection and prevention
​
OR01, OR02, OR03, OR04
16:30-17:00
Coffee Break
17.00-19.00
Session 2: Preclinical and clinical gene editing for gene therapy
Chairs:
​
17:00 Matthew Porteus, Stanford University
INV04 : Genome Editing of Stem Cells: Applications to Genetic and Non-Genetic Diseases.
​
​17:30 Mario Amendola, Genethon, Evry​
INV05 Engineering Hematopoietic stem cells by targeted gene addition
​​
​18:00 Paula Rio, Ciemat/Ciberer, Madrid​
INV06 Advancing Hematopoietic Stem Cell Gene Therapy in Fanconi Anemia
​
OR05, OR06
20:00
Party at Mama Shelter
Thursday 20 March
08:30-09:00
Registration
09.00-10.45
Session 3: AAV and lentiviral vectors for gene therapy
Chair:
Alessio Cantore, SR-Tiget, Milano
INV07 Deliver to the liver: towards one-and-done gene therapies for defects of hepatic metabolism
Hildegard Büning, Hannover Medical School
INV08 Tailored biological nanoparticles for in vivo gene therapy
OR07, OR08, OR09
10:45-11:15
Coffee Break
11.15-12.45
Session 4: Cancer Therapy I - Immunotherapy and CAR-T cells
Chair:
11:15 Naomi Taylor, Université de Montpellier, NIH
INV09 Harnessing TCR-controlled fuzzy logic to achieve immunotherapeutic precision of CAR T-cells
11:45 Els Verhoeyen, University of Nice
INV10 T-cell targeted lentiviral pseudotypes for in vivo CAR T cell cancer therapy
​
OR10, OR11​
12:45-13:45
Lunch
13:45-14:45
Poster session
14.45-16.45
Session 5: Disease model : IPSc and organoids cell therapy
Chair:
Olivier Goureau, Institut de la Vision, Paris
INV11 Retinal organoids for modeling inherited retinal diseases and developing new therapeutic strategies
Jens Schwamborn, University of Luxemburg
INV12 Patient specific midbrain organoids and assembloids for in vitro disease modeling
Saverio Tedesco, UCL London​
INV13 Engineering human skeletal muscle for advanced modelling of neuromuscular diseases and gene therapies.
​
OR12, OR13
16:45-17:15
Coffee Break
17.15-18.45
Session 6: Gene therapy for genetic diseases
Chair:
Françoise Piguet, ICM, Paris
INV14 Gene therapy of lysosomal storage disorders
​
Matthias Titeux, Institut Imagine, Paris
INV15 Splice modulation strategies using antisense oligonucleotides for Dystrophic Epidermolysis Bullosa
​​
OR14, OR15
18:45-20:15
Poster session 2
Friday 21 March
08:30-09:00
Registration
09.00-10.30
Session 7: Cancer therapy II
Chair:
09:00 Mario Squadrito, SR-Tiget, Milan
INV16 In vivo liver macrophage engineering for cancer immunotherapy
​
09:30 Laurie Menger, Institut Gustave Roussy
INV17 In vivo genome-wide CRISPR screens for advanced T cell therapy
OR16, OR17
10:30-11:00
Coffee Break
11.00-12.45
Session 8: Non-viral vector / nanotechnology for gene editing
Chair:
Jacob Giehm Mikkelsen, Aarhus University
INV18 Engineered lentivirus-derived particles for CRISPR RNP delivery and prime editing
​
Zoltan Ivics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig
INV19 Advances in Sleeping Beauty transposon engineering of therapeutic cells
​​
OR18, OR19, OR20
12:45-14:00
Lunch and posters
14.00-15.45
Session 9: Innovative approaches
Chair:
14:00 Jean-Luc Perfettini, Gustave Roussy, Paris
INV20 Next-generation human chimeric antigen receptor monocytes for cancer immunotherapy.
​
14:30 Guy Lenaers, Université d'Angers
INV21 RNA trans-splicing based gene therapy: a relevant approach to treat diseases related to complex genes.
​​
OR21, OR22, OR23
16.00-16.45
Session 10: Closing keynote
Chair:
16:00 Alessandro Aiuti, SR-Tiget, Milan
INV22 Hematopoietic stem cell gene therapy for genetic diseases
16:45-17:00
Poster and oral presentation awards